Valuation: Center Laboratories, Inc.

Market Cap 24.48B 770M 676M 638M 582M 1.09B 73.84B 1.1B 7.64B 2.96B 37.72B 2.89B 2.83B 121B P/E 2024
-28.2x
P/E 2025 3.64x
Enterprise Value 28.52B 898M 788M 744M 678M 1.27B 86.03B 1.28B 8.9B 3.45B 43.95B 3.37B 3.3B 141B EV / Sales 2024
22.3x
EV / Sales 2025 23.1x
Free-Float
72.61%
Yield 2024
1.71%
Yield 2025 4.2%
08-11 Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-20 GenEditBio Limited announced that it has received TWD 550 million in funding from Center Laboratories, Inc. CI
05-13 Center Laboratories says Jan-Mar net profit at T$1.97 bln RE
05-13 Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-13 Center Laboratories, Inc. announces Annual dividend, payable on September 11, 2026 CI
03-31 WuXi XDC Cayman Inc. completed the acquisition of 60% stake in BioDlink International Company Limited from a group of shareholders. CI
03-03 Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-13 WuXi XDC Cayman Inc. proposed to acquire 60% stake in BioDlink International Company Limited from a group of shareholders for HKD 1.9 billion. CI
11-11 Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-12 Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-06-09 Tranche Update on Center Laboratories, Inc.'s Equity Buyback Plan announced on April 9, 2025. CI
25-06-08 Center Laboratories, Inc.'s Equity Buyback announced on April 9, 2025, has expired with 9,909,000 shares, representing 1.38% for TWD 383.08 million. CI
25-05-11 Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 day-1.75%
1 week+0.16%
Current month-0.96%
1 month-3.58%
3 months-12.65%
6 months-21.51%
Current year-21.89%
1 week 30.55
Extreme 30.55
31.5
1 month 29.35
Extreme 29.35
31.95
Current year 29.35
Extreme 29.35
48.96
1 year 29.35
Extreme 29.35
48.96
3 years 27.74
Extreme 27.739294
54.03
5 years 27.74
Extreme 27.739294
56
10 years 19.99
Extreme 19.990785
61.16
Manager TitleAgeSince
Chief Executive Officer - 1998-08-02
Director of Finance/CFO - 2022-12-07
Director of Finance/CFO - 2000-07-31
Director TitleAgeSince
Chairman - 2022-11-29
Director/Board Member 61 2010-06-13
Director/Board Member - 2010-06-13
Change 5-day change 1-year change 3-year change Capi.($)
-1.75%+0.16%-12.12%-24.46% 770M
+0.13%+2.65%+63.34%+115.17% 1,055B
+0.20%+0.46%+50.92%+70.56% 654B
-0.29%+0.14%+19.82%+71.75% 467B
-0.85%+0.98%+42.13%+44.64% 348B
+0.71%+4.08%+21.75%+28.83% 275B
+1.23%+0.42%+14.11%+12.43% 258B
+2.11%+7.51%+51.88%+54.11% 224B
+0.83%+0.55%+34.64%+99.83% 187B
0.00%-10.14%-27.40%-61.08% 171B
Average +0.23%+0.68%+25.91%+41.18% 363.91B
Weighted average by Cap. +0.27%+1.32%+40.41%+68.20%

Financials

2024 2025
Net sales 1.62B 50.91M 44.67M 42.19M 38.45M 71.98M 4.88B 72.49M 505M 196M 2.49B 191M 187M 8.01B 1.52B 47.71M 41.87M 39.54M 36.03M 67.46M 4.57B 67.94M 473M 183M 2.34B 179M 175M 7.51B
Net income -1.1B -34.73M -30.48M -28.78M -26.23M -49.1M -3.33B -49.45M -344M -133M -1.7B -130M -128M -5.47B 9.32B 293M 257M 243M 222M 415M 28.12B 418M 2.91B 1.13B 14.37B 1.1B 1.08B 46.17B
Net Debt 4.48B 141M 124M 117M 106M 199M 13.51B 201M 1.4B 542M 6.9B 529M 518M 22.18B 4.04B 127M 112M 105M 96.05M 180M 12.19B 181M 1.26B 489M 6.23B 477M 467M 20.01B
Logo Center Laboratories, Inc.
Center Laboratories Inc is a Taiwan-based company engaged in the development of pharmaceutical products. The Company's products mainly focus on internal liquids, including syrups, suspensions, liquids and other dosage forms. Pharmacological classifications include respiratory tract therapeutics such as cough suppressants, sputum expectorants, asthma medications, and runny nose relief, while antipyretic and analgesic medications and gastrointestinal medications are also in great demand, and a variety of internal liquids and lozenges for the treatment of central nervous system (CNS) such as epilepsy, dysphoria, dementia, and Parkinson's disease have already been introduced into the market. The Company is a specialized manufacturer of internal liquid.
Employees
-
Date Price Change Volume
26-09-24 NT$30.95 -1.75% 1,177,578
26-09-23 NT$31.50 +1.61% 1,403,197
26-09-22 NT$31.00 +0.81% 1,568,142
26-09-21 NT$30.75 -0.49% 943,566
26-09-18 NT$30.90 +0.32% 1,494,037
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. 4123 Stock